Abstract

Previous studies have demonstrated that sulforaphane (SFN) is a promising agent against osteoclastic bone destruction. However, the mechanism underlying its anti-osteoclastogenic activity is still unclear. Herein, for the first time, we explored the potential role of autophagy in SFN-mediated anti-osteoclastogenesis in vitro and in vivo. We established an osteoclastogenesis model using receptor activator of nuclear factor kappa-β ligand (RANKL)-induced RAW264.7 cells and bone marrow macrophages (BMMs). Tartrate-resistant acid phosphatase (TRAP) staining showed the formation of osteoclasts. We observed autophagosomes by transmission electron microscopy (TEM). In vitro, we found that SFN inhibited osteoclastogenesis (number of osteoclasts: 22.67 ± 0.88 in the SFN (0) group vs. 20.33 ± 1.45 in the SFN (1 μM) group vs. 13.00 ± 1.00 in the SFN (2.5 μM) group vs. 6.66 ± 1.20 in the SFN (2.5 μM) group), decreased the number of autophagosomes, and suppressed the accumulation of several autophagic proteins in osteoclast precursors. The activation of autophagy by rapamycin (RAP) almost reversed the SFN-elicited anti-osteoclastogenesis (number of osteoclasts: 22.67 ± 0.88 in the control group vs. 13.00 ± 1.00 in the SFN group vs. 17.33 ± 0.33 in the SFN+RAP group). Furthermore, Western blot (WB) analysis revealed that SFN inhibited the phosphorylation of c-Jun N-terminal kinase (JNK). The JNK activator anisomycin significantly promoted autophagy, whereas the inhibitor SP600125 markedly suppressed autophagic activation in pre-osteoclasts. Microcomputed tomography (CT), immunohistochemistry (IHC), and immunofluorescence (IF) were used to analyze the results in vivo. Consistent with the in vitro results, we found that the administration of SFN could decrease the number of osteoclasts and the expression of autophagic light chain 3 (LC3) and protect against lipopolysaccharide (LPS)-induced calvarial erosion. Our findings highlight autophagy as a crucial mechanism of SFN-mediated anti-osteoclastogenesis and show that the JNK signaling pathway participates in this process.

Highlights

  • Throughout life, bone remodeling is precisely regulated by the balance between osteoblastic bone formation and osteoclastic bone resorption

  • We demonstrate the effects of SFN on bone resorption in mice with lipopolysaccharide (LPS)-induced erosion of the calvarial bone and we investigated the alterations of autophagy in this process

  • We found that cell viability decreased along a gradient by treating RAW264.7 cells and bone marrow macrophages (BMMs) with various concentration SFN (0, 0.5, 1, 2.5, 5, 10, 20 μM, Figure 1a)

Read more

Summary

Introduction

Throughout life, bone remodeling is precisely regulated by the balance between osteoblastic bone formation and osteoclastic bone resorption. This balance is often disturbed by diseases associated with excessive bone resorption, such as osteoporosis, rheumatoid arthritis (RA), periodontitis, and bone metastasis [1,2,3]. Recent studies have implicated changes in autophagy in osteoclast-related diseases such as osteoporosis and RA [12,13]. Carl et al suggested that the Atg5–Atg complex is crucial for osteoclastic lysosome localization and bone resorption and that its deficiency could impair the formation of osteoclasts’ ruffled border, resulting in osteopetrosis [15]. We demonstrate the effects of SFN on bone resorption in mice with lipopolysaccharide (LPS)-induced erosion of the calvarial bone and we investigated the alterations of autophagy in this process

SFN Inhibited Osteoclastogenesis in a Dose-Dependent Manner
Rapamycin Reversed SFN-Mediated Anti-Osteoclatogenic Effects
Discussion
Reagents and Mice
Immunofluorescence Analysis
Western Blot Assay
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call